<html><body><h1>Case: 1316243</h1>
77.0 year old Asian_or_Pacific-Islander_Non-Hispanic Male
<p><b>Numeric Data Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">77</td><td width="200">1970-1-1 (2440588)</td></tr>
<tr><td width="200">Calcium</td><td width="200">9</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">119</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Glucose</td><td width="200">131</td><td width="200">1975-10-16 (2442702)</td></tr>
<tr><td width="200">Phosphorus</td><td width="200">4</td><td width="200">1979-4-24 (2443988)</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">49</td><td width="200">1979-2-8 (2443913)</td></tr>
<tr><td width="200">Chloride</td><td width="200">107.0</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">54</td><td width="200">1979-2-8 (2443913)</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">75</td><td width="200">1979-6-15 (2444040)</td></tr>
<tr><td width="200">BNP</td><td width="200">2,072</td><td width="200">1979-4-16 (2443980)</td></tr>
<tr><td width="200">B 12</td><td width="200">919.0</td><td width="200">1978-10-26 (2443808)</td></tr>
<tr><td width="200">Weight</td><td width="200">155</td><td width="200">1979-6-15 (2444040)</td></tr>
<tr><td width="200">HbA1C</td><td width="200">6.1</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">87</td><td width="200">1979-2-8 (2443913)</td></tr>
<tr><td width="200">Urine_ALB/CREAT_RATIO_spot</td><td width="200">110</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Urine_Alb/creat_Ratio_24h</td><td width="200">110</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">108</td><td width="200">1979-2-8 (2443913)</td></tr>
<tr><td width="200">SGOT</td><td width="200">32</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">132</td><td width="200">1979-6-15 (2444040)</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">1</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Height</td><td width="200">64</td><td width="200">1979-6-12 (2444037)</td></tr>
<tr><td width="200">Potassium</td><td width="200">3.8</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">110</td><td width="200">1979-2-8 (2443913)</td></tr>
<tr><td width="200">BUN</td><td width="200">23</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">HCT</td><td width="200">30</td><td width="200">1979-4-18 (2443982)</td></tr>
<tr><td width="200">HGB</td><td width="200">10</td><td width="200">1979-4-18 (2443982)</td></tr>
<tr><td width="200">Sodium</td><td width="200">141</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Albumen</td><td width="200">3.6</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.1</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">UrineAlbumin_24H</td><td width="200">170</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">6.1</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">UrineAlbumin_SPOT</td><td width="200">170</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Pulse</td><td width="200">72</td><td width="200">1979-6-15 (2444040)</td></tr>
<tr><td width="200">PLT</td><td width="200">130</td><td width="200">1979-4-18 (2443982)</td></tr>
<tr><td width="200">WBC</td><td width="200">6</td><td width="200">1979-4-18 (2443982)</td></tr>
<tr><td width="200">eGFR</td><td width="200">38</td><td width="200">1979-4-24 (2443988)</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1979-4-30 (2443994)</td></tr>
<tr><td width="200">SGPT</td><td width="200">50</td><td width="200">1979-5-28 (2444022)</td></tr>
</table>
<p><b>Medications:</b> furosemide(25.0[null:0, null]) Insulin(0.05[null:0, null]) metformin(1250.0[null:0, null]) simvastatin(50.0[null:0, null]) tamsulosin(0.5[null:0, null]) terazosin(15.0[null:0, null]) triamterene(20.0[null:0, null]) 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Parameter</b></td> <td width="200"><b>Value</b></td><td width="200"><b>Dates</b></td></tr>
<tr><td width="200">Angina</td><td width="200"></td><td width="200">1978-3-27</td></tr>
<tr><td width="200">Asthma</td><td width="200"></td><td width="200">1978-3-27</td></tr>
<tr><td width="200">Atrial Fibrillation</td><td width="200"></td><td width="200">1979-5-16</td></tr>
<tr><td width="200">Cardiomegaly</td><td width="200"></td><td width="200">1978-11-26</td></tr>
<tr><td width="200">Coronary Artery Disease</td><td width="200"></td><td width="200">1979-4-30</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200"></td><td width="200">1978-9-26</td></tr>
<tr><td width="200">Diabetes Type 2</td><td width="200"></td><td width="200">1979-4-30</td></tr>
<tr><td width="200">edema</td><td width="200"></td><td width="200">1978-6-22</td></tr>
<tr><td width="200">Heart Block</td><td width="200"></td><td width="200">1978-6-19</td></tr>
<tr><td width="200">Heart Failure HTN</td><td width="200"></td><td width="200">1979-6-12</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1979-3-28</td></tr>
<tr><td width="200">Has Pacemaker</td><td width="200"></td><td width="200">1979-4-16</td></tr>
<tr><td width="200">BPH</td><td width="200"></td><td width="200">1978-7-19</td></tr>
<tr><td width="200">Unspecified AV Block</td><td width="200"></td><td width="200">1979-1-25</td></tr>
<tr><td width="200">Race</td><td width="200">Asian_or_Pacific-Islander_Non-Hispanic</td><td width="200"></td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
</table><p>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> achieved(LDL_Cholesterol(49.0:02/08/1979))
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(75) && Treatment_Systolic_BP(132))
<p><b>Action Choices</b>
<ul>
<li><b>Stage C HF</b><br>
<ul>
</ul>
<li><b> </b><br>
<ul>
<li><b>General Recommendations <font color=FF0000>preferred</font></b>(strict rule-in condition<i> HF ICD9 code OR( signs and structural abnormality)</i> evaluate to <b> true</b> )])
[Class I]Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)
[Class II a]It is reasonable to treat patients with atrial fibrillation and HF with a strategy to maintain sinus rhythm or with a strategy to control ventricular rate alone. (Level of Evidence: A)
[Class II a]Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)
[Class I]Continue to manage diuretics and salt restriction for optimal volume control.  (Level of Evidence: C)

<li><b>Referrals <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
Class I
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Beta blocker for stage C heart failure
<ul>
<li>preferred drug: Bisoprolol, Sustained release metoprolol succinate, Carvedilol</li>
<li>preference: neutral
<li>No comment
</ul>
<li>Beta blocker Stage C with MI
<ul>
<li>preferred drug: Carvedilol</li>
<li>[Recommendation] Refer to 2013 ACCF/AHA Guideline (reproduced below) for specific BB starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
bisoprolol starting dose 1.25 mg once; max dose 10 mg once
carvedilol starting dose 3.125 mg twice; max dose 50 mg twice
carvedilol CR starting dose 10 mg once; max dose 80 mg once
metoprolol succinate ER starting dose 12.5 - 25 mg once; 200 mg once
<li>preference: neutral
</ul>
<li>Ace_Inhibitor
<ul>
<li>preferred drug: Enalapril</li>
<li>[Recommendation] Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>[Recommendation] Renal function and
serum potassium should be assessed within 1 to 2 weeks of
initiation of therapy and periodically thereafter, especially in
patients with preexisting hypotension, hyponatremia, diabetes
mellitus, or azotemia or in those taking potassium
supplements.
<li>[Recommendation] Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs
<li>preference: neutral
</ul>
<li>Aldosterone Antagonist
<ul>
<li>[Recommendation] Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who CAN BE CAREFULLY MONITORED for PRESERVED RENAL FUNCTION and NORMAL POTASSIUM concentration. Creatinine should be 2.5 mg per dL or less in men or 2.0 mg per dL or less in women and potassium should be less than 5.0 mEq per liter. Under circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone anatgonists.
<li>preference: neutral
</ul>
<li>hydralazine and nitrates
<ul>
<li>[Recommendation] Recommend starting with hydralazine 25mg tid and nitrates 10mg tid. Would not go much above hydralazine 50mg tid and nitrates 40mg tid. Titrate after a month. Beta blockers can avoid the tachycardia caused by hydralazine and nitrates.
<li>[Class I] The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated (423, 424). (Level of Evidence: A)
<li>preference: neutral
</ul>
</ul>
